Phase 2 Study of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment
From Business Wire NewsExpress - Jul 07, 2008
NEW YORK--(BUSINESS WIRE)--Jul 7, 2008 - ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in adolescents and adult patients with several types of soft tissue sarcoma has opened for patient enrollment.
to read whole article:
to read summary: